Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

NCT04343651 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus Disease 2019

Interventions

DRUG: Placebo
DRUG: Leronlimab (700mg)

Sponsor

CytoDyn, Inc.